Sirtris Pharmaceuticals, Inc. (SIRT) Announced Receipt of Cash Tender Offer for Outstanding Shares from GlaxoSmithKline plc
Sirtris Pharmaceuticals, Inc. (SIRT), a biopharmaceutical company that develops proprietary, orally available, small molecule drugs to treat metabolic diseases, announced in early May the receipt of a cash tender offer for outstanding company shares. Fountain Acquisition Corporation, a wholly-owned subsidiary of GlaxoSmithKline plc (GSK), has begun a cash tender offer to purchase all outstanding shares of common stock of Sirtris. The offer is for $22.50 in cash without interest and less any required withholding taxes. The offer is being made pursuant to a previously announced definitive agreement dated April 22, 2008 among Sirtris, Fountain Acquisition Corporation and SmithKline Beecham Corporation,…